Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index

被引：0
|
作者：
M A N Sendur
S Aksoy
N Zengin
K Altundag
机构：
[1] Ankara Numune Education and Research Hospital,Department of Medical Oncology
[2] Sihhiye,Department of Medical Oncology
[3] Ankara 06100,undefined
[4] Turkey,undefined
[5] Hacettepe University Cancer Institute,undefined
来源：
British Journal of Cancer | 2012年 / 107卷
关键词：
postmenopausal; breast cancer; letrozole; anastrozole;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1815 / 1819
页数：4
相关论文
共 50 条
  • [1] Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index
    Sendur, M. A. N.
    Aksoy, S.
    Zengin, N.
    Altundag, K.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 107 (11) : 1815 - 1819
  • [2] Efficacy of adjuvant tamoxifen in hormone receptor-positive premenopausal breast cancer patients according to the body mass index
    Altundag, Kadri
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Ozisik, Yavuz
    [J]. CANCER RESEARCH, 2015, 75
  • [3] Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Ozdemir, Nuriye Y.
    Zengin, Nurullah
    Yazici, Ozan
    Sever, Ali R.
    Altundag, Kadri
    [J]. JOURNAL OF BUON, 2016, 21 (01): : 27 - 34
  • [4] Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review
    S. J. Ioannides
    P. L. Barlow
    J. M. Elwood
    D. Porter
    [J]. Breast Cancer Research and Treatment, 2014, 147 : 237 - 248
  • [5] Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review
    Ioannides, S. J.
    Barlow, P. L.
    Elwood, J. M.
    Porter, D.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (02) : 237 - 248
  • [6] Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer.
    Cuzick, J
    Howell, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 43S - 43S
  • [7] Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer
    Lippman, Marc
    [J]. LANCET ONCOLOGY, 2019, 20 (03): : 312 - 313
  • [8] The effect of using adjuvant aromatase inhibitors on cognitive functions in postmenopausal women with hormone receptor-positive breast cancer
    Ilhan, Rukiye Guler
    Ilhan, Yusuf
    Goksu, Sema Sezgin
    Tatli, Ali Murat
    Coskun, Hasan Senol
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) : S368 - S372
  • [9] Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor-positive breast cancer patients: upfront or sequential?
    Dediu, M.
    Median, D.
    Alexandru, A.
    Vremes, G.
    Gal, C.
    Gongu, M.
    [J]. JOURNAL OF BUON, 2009, 14 (03): : 375 - 379
  • [10] Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy
    Sulaica, Elisabeth
    Han, Tiffany
    Wang, Weiqun
    Bhat, Raksha
    Trivedi, Meghana V.
    Niravath, Polly
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 203 - 210
12345